Harjaningsih, W. and Ikawati, Z. and Mustofa, Mustofa and Fitrianis, Fitrianis and Khoirunnisa, R.S. and Istivada, N. (2023) Correlation between clozapine use and metabolic syndrome in schizophrenic patients. Pharmacy Education, 23 (2). pp. 103-112. ISSN 15602214
Correlation between clozapine use and metabolic syndrome in schizophrenic patients.pdf - Published Version
Restricted to Registered users only
Download (389kB) | Request a copy
Abstract
Background: Clozapine, an atypical antipsychotic agent, is effective for relapse or refractory schizophrenia that has failed to respond to other antipsychotic medications. Despite its effectiveness, clozapine has a higher risk of metabolic syndrome than other antipsychotics. Objective: This research aimed to identify the correlation between clozapine and metabolic syndrome, such as obesity, cholesterol, and blood glucose levels, in schizophrenic patients at Ghrasia Mental Hospital, Yogyakarta, Indonesia. Method: This is a cross-sectional research. Subjects who met the inclusion criteria were randomly sampled from outpatients between November 2021 and February 2022. The research collected medical record data (characteristic patients, medication patterns, and body mass index) and analysed blood profiles (cholesterol and glucose levels). The data were analysed descriptively and statistically. Result: Among the 71 patients in this research, 37 (52.11) were male and 34 (47.89) were female, with an average age of 36-45 years. The treatment patterns of patients were as follows: 44 were taking only clozapine and 27 patients did not use clozapine. Clozapine was frequently combined with risperidone and haloperidol in this research. Bivariate analysis using Fisher's Exact test revealed no significant correlation between clozapine use, clozapine regimen (single or combined), duration of clozapine therapy (>= 5 years), and clozapine dose (high or low) with obesity, hypercholesterolemia, and hyperglycemia. Meanwhile, multivariate analysis revealed a significant correlation between gender and obesity (p < 0.05), with women having a 0.299 higher risk than men. The effects of age and duration of schizophrenia on hypercholesterolemia and hyperglycemia were insignificant. Conclusion: There was no correlation found between clozapine use and metabolic syndrome. Gender was found to have a significant correlation with obesity in the research. © 2023 FIP.
Item Type: | Article |
---|---|
Additional Information: | cited By 0 |
Uncontrolled Keywords: | aripiprazole; chlorpromazine; cholesterol; clozapine; fluphenazine; glucose; haloperidol; quetiapine; risperidone; trifluoperazine, adolescent; adult; age; aged; Article; body mass; cholesterol blood level; cross-sectional study; demographics; descriptive research; disease duration; drug use; female; glucose blood level; human; hypercholesterolemia; hyperglycemia; Indonesia; major clinical study; male; medical record review; metabolic syndrome X; middle aged; obesity; schizophrenia; sex difference |
Subjects: | R Medicine > RC Internal medicine > RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry |
Divisions: | Faculty of Medicine, Public Health and Nursing > Nursing |
Depositing User: | Ani PURWANDARI |
Date Deposited: | 22 Aug 2024 08:32 |
Last Modified: | 22 Aug 2024 08:32 |
URI: | https://ir.lib.ugm.ac.id/id/eprint/2920 |